Compare Revvity Inc (RVTY) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Global X SuperDividend ETF — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while Global X SuperDividend ETF trades at $24.57. The key difference: Revvity Inc pays a 0.24% dividend while Global X SuperDividend ETF pays none, and Revvity Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | SDIV | |
|---|---|---|
Market Cap | $12.91B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $117.75 | $26.34 |
52-Week Low | $82.26 | $22.90 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
SDIV, a US-listed ETF, trades at $24.585, down 0.26% on the day, with a bearish technical signal driven by moving averages. The fund offers a high dividend yield, with recent payouts of $0.18 per share. Technical indicators show neutral oscillators but overall selling pressure, with key support at $24 and resistance at $25.
The outlook for SDIV hinges on income-seeking demand amid market volatility, as highlighted by financial media. Risks include sensitivity to interest rates and geopolitical factors. Analyst sentiment is mixed, with some upgrades citing yield attractiveness, but the bearish technical trend warrants caution for near-term price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
